European Commission (EC) Publishes Approval Of Octapharma AG’s Human Cell Line Recombinant FVIII (Nuwiq®) Across All Age Groups In Haemophilia A
8/6/2014 10:12:06 AM
LACHEN, Switzerland--(BUSINESS WIRE)--The European Commission has published approval of Octapharma’s Nuwiq® (simoctocog alfa) for the treatment and prophylaxis of bleeding in all age groups with haemophilia A (congenital factor VIII [FVIII] deficiency). Nuwiq® is the newest generation of FVIII replacement, produced in a human cell line cultured without additives of human or animal origin. Nuwiq® is devoid of antigenic non-human protein epitopes and has a high affinity for the von Willebrand coagulation factor, both of which are potentially important properties in reducing FVIII inhibitor formation. The development of Nuwiq® aimed to address the challenges of inhibitor formation as well as the frequent infusions required for prophylaxis of bleeding.
Help employers find you! Check out all the jobs and post your resume.
comments powered by